Second generation systemic photosensitizing agent. Prepn: R. Bonnett, M. C. Berenbaum, EP 337601; eidem, US 4992257 (1989, 1991 both to Efamol Holdings); R. Bonnett et al., Biochem. J. 261, 277 (1989). NMR study: idem et al., J. Chem. Soc. Perkin Trans. 2 1994, 1839. Toxicology study: R. B. Veenhuizen et al., Int. J. Cancer 59, 830 (1994). HPLC determn in plasma and tissue: M. Barberi-Heyob et al., J. Chromatogr. B 688, 331 (1997). Clinical pharmacokinetics: T. Glanzmann et al., Photochem. Photobiol. 67, 596 (1998). Clinical evaluation in photodynamic therapy of malignancies: J.-F. Savary et al., Arch. Otolaryngol. Head Neck Surg. 123, 162 (1997).
Antineoplastic (photosensitizer).
Antineoplastic (Photosensitizer)